Effectiveness and cost-effectiveness of an optimized process of providing assistive technology for impaired upper extremity function: Protocol of a prospective, quasi-experimental non-randomized study (OMARM)

Autor: Huub Creemers, Edith A. V. Hagedoren, Uta Roentgen, Loek A. van der Heide, Ingrid E. H. Kremer, Ramon Daniëls, M.A. Brehm, Silvia M. A. A. Evers, Jan T. Groothuis
Přispěvatelé: Rehabilitation medicine, AMS - Rehabilitation & Development, Health Services Research, RS: CAPHRI - R2 - Creating Value-Based Health Care
Rok vydání: 2021
Předmět:
Zdroj: Technology and Disability, 33(3), 207-220. IOS Press BV
Technology and Disability, 33, 207-220
Technology and Disability, 33(3), 207-220. IOS Press
Technology and Disability, 2021(33), 207-220
Technology and Disability, 33, pp. 207-220
ISSN: 1055-4181
Popis: BACKGROUND: Impaired upper extremity function due to muscle paresis or paralysis has a major impact on independent livingand quality of life (QoL). Assistive technology (AT) for upper extremity function (i.e. dynamic arm supports and robotic arms) canincrease a client’s independence. Previous studies revealed that clients often use AT not to their full potential, due to suboptimalprovision of these devices in usual care.OBJECTIVE: To optimize the process of providing AT for impaired upper extremity function and to evaluate its (cost-)effectiveness compared with care as usual.METHODS: Development of a protocol to guide the AT provision process in an optimized way according to generic Dutchguidelines; a quasi-experimental study with non-randomized, consecutive inclusion of a control group (n = 48) receiving care asusual and of an intervention group (optimized provision process) (n = 48); and a cost-effectiveness and cost-utility analysis fromsocietal perspective will be performed. The primary outcome is clients’ satisfaction with the AT and related services, measuredwith the Quebec User Evaluation of Satisfaction with AT (Dutch version; D-QUEST). Secondary outcomes comprise complaintsof the upper extremity, restrictions in activities, QoL, medical consumption and societal cost. Measurements are taken at baselineand at 3, 6 and 9 months follow-up.
Databáze: OpenAIRE